Safety aspects of parenteral iron in patients with end-stage renal disease

Drug Safety

Volumn 17, Issue 4, 1997, Pages 241-250

  Sunder Plassmann, Gere ^a   Hörl, Walter H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FERROUS GLUCONATE; IRON; IRON DEXTRAN; IRON POLYMALTOSE; IRON SACCHARATE; IRON SORBITEX; TRANSFERRIN;

ABDOMINAL PAIN; ANAPHYLAXIS; ARTHRALGIA; BRONCHOSPASM; CLINICAL TRIAL; DRUG COST; DRUG SAFETY; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; FEVER; FLUSHING; HEADACHE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON OVERLOAD; IRON THERAPY; KIDNEY FAILURE; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; META ANALYSIS; MYALGIA; NAUSEA; PARENTERAL NUTRITION; PHLEBITIS; PRIORITY JOURNAL; PRURITUS; REPERFUSION INJURY; REVIEW; SEIZURE; THORAX PAIN; URTICARIA; VOMITING;

EID: 0030669662     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199717040-00004     Document Type: Review

References (75)

1. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316: 73-8
2. Winearls CG, Pippard MJ, Downing MR, et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; 11: 1175-8
3. Macdougall IC, Cavill I, Hulme B, et al. Detection of functional iron deficiency during erythropoietin treatment: a new approach. BMJ 1992; 304: 225-6
4. Schaefer RM, Schaefer L. Management of iron substitution during r-HuEPO therapy in chronic renal failure patients. Erythropoiesis 1992; 3: 71-5
5. Schaefer RM, Schaefer L. The hypochromic red cell: a new parameter for monitoring of iron supplementation during rhEPO therapy. J Perinat Med 1995; 23: 83-8
6. Koch KM, Patyna WD, Shaldon S, et al. Anemia of the regular hemodialysis patient and its treatment. Nephron 1974; 12: 405-19
7. Anastassiades EG, Howarth D, Howarth J, et al. Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant 1993; 8: 846-53
8. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41-6
9. Levin NW, Lazarus JM, Nissenson AR. National cooperative rHu erythropoietin study in patients with chronic renal failure: an interim report. Am J Kidney Dis 1993; 22 Suppl. 1: 3-12
10. Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients with erythropoietin. Kidney Int 1996; 50: 1694-9
11. Sepandj F, Jindal K, West M, et al. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 1996; 11: 319-22
12. Silverberg DS, Blum M, Peer G, et al. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996; 72: 413-7
13. Silverberg DS, Iaina A, Peer G, et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 1996; 27: 234-8
14. Sunder-Plassmann G, Hörl WH. Iron metabolism and iron substitution during erythropoietin therapy. Clin Investig 1994; 72: S11-5
15. Sunder-Plassmann G, Hörl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995; 10: 2070-6
16. Kooistra MP, Marx JJM. The management of iron metabolism in recombinant human erythropoietin treated dialysis patients by Dutch nephrologists. Nephrol Dial Transplant 1997; 12: 879-83
17. Young EW, Bloembergen WE, Woods JD, et al. Iron use among erythropoietin-treated U.S. hemodialysis patients [abstract]. J Am Soc Nephrol 1996; 7: 1469
18. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittel Forschung 1992; 42: 1439-52
19. Danielson BG, Geisser P, Schneider W. In: Iron therapy. St Gallen: Vifor (International) Inc., 1996
20. Roe DJ, Harford AM, Zager PG, et al. Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: a prospective analysis and comparison of two agents. Am J Kidney Dis 1996; 28: 855-60
21. Kumpf VJ, Holland EG. Parenteral iron dextran therapy. DICP 1990; 24: 162-6
22. Wood JK, Milner PFA, Pathak UN. The metabolism of iron-dextran given as a total-dose infusion to iron deficient Jamaican subjects. Br J Haematol 1968; 14: 119-29
23. Henderson PA, Hillman RS. Characteristics of iron dextran utilization in man. Blood 1969; 34: 357-75
24. Beamish MR, Davies AG, Eakins JD, et al. The measurement of reticuloendothelial iron release using iron-dextran. Br J Haematol 1971; 21: 617-22
25. Davies AG, Beamish MR, Jacobs A. Utilization of iron dextran. BMJ 1971; 1: 146-7
26. Kotaki M, Uday K, Henriquez M, et al. Intravenous iron therapy in hemodialysis [abstract]. J Am Soc Nephrol 1996; 7: 1452
27. Kaufman J, Reda D, Goldfarb D, et al. Diagnosis and treatment of iron deficiency in patients on maintenance recombinant human erythropoietin (rHuEPO) [abstract]. J Am Soc Nephrol 1996; 7: 1450
28. Marchasin S, Wallerstein RO. The treatment of iron deficient anemia with intravenous iron dextran. Blood 1964; 23: 354-8
29. Suh H, Wadhwa NK. Iron dextran treatment in peritoneal dialysis patients on erythropoietin. Adv Perit Dial 1992; 8: 464-6
30. Burns DL, Mascioli EA, Bistrian BR. Parenteral iron dextran therapy: a review. Nutrition 1995; 11: 163-8
31. Fishbane S, Ungureanu VD, Maeska JK, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28: 529-34
32. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980; 243: 1726-31
33. St Peter WL, Lambrecht LJ, Macres M. Randomised cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28: 523-8
34. Fleming LW, Stewart WK, Parratt D. Dextran antibodies, complement conversion and circulating immune complexes after intravenous iron dextran therapy in dialysed patients. Nephrol Dial Transplant 1992; 7: 35-9
35. Keppler BH. Pharmacology of iron gluconate: recent advances. Kidney Int. In press
36. Allegra V, Mengozzi G, Vasile A. Iron deficiency in maintenance hemodialysis patients: assesment of diagnosis criteria and of three different iron treatments. Nephron 1991; 57: 175-82
37. Taylor JE, Peat N, Porter C, et al. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 1079-83
38. Nissenson AR, Lindsay RM, Swan S, et al. Ferric gluconate (Ferrlecit™) is safe and effective on hemodialysis (HD) patients (PTS): North American trial [abstract). J Am Soc Nephrol 1996; 7: 1459
39. Pascual J, Teruel JL, Liano E, et al. Sodium ferric gluconate complex given intravenously for iron deficiency in hemodialysis [letter]. Clin Nephrol 1991; 35: 87
40. Calvar C, Mata D, Alonso C, et al. Intravenous administration of iron gluconate during haemodialysis. Nephrol Dial Transplant 1997; 12: 574-5
41. Zunen AL, Adriaansen HJ, van Bommel EFH, et al. Oversaturation of transferrin after intravenous ferric gluconate (Ferrlecit®) in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 820-4
42. Navarro JF, Teruel JL, Liano F, et al. Effectiveness of intravenous administration of Fe-gluconate-Na complex to maintain adequate body iron stores in hemodialysis patients. Am J Nephrol 1996; 16: 268-72
43. Nissenson AR, Swan S, Lambrecht LL, et al. Ferric gluconate (Ferrlecit™) is safe in hemodialysis (HD) patients (PTS) who react to iron dextran [abstract]. J Am Soc Nephrol 1996; 7: 1460
44. Braun J, Lindner K, Schreiber M, et al. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant 1997; 12: 1173-81
45. Granolleras C, Oulés R, Branger B, et al. Iron supplementation of hemodialysis patients receiving recombinant human erythropoietin therapy. In: Bauer C, Koch KM, Scigalla P, et al., editors. Erythropoietin: molecular physiology and clinical applications. New York: Marcel Dekker Inc., 1993: 211-6
46. Sunder-Plassmann G, Hörl WH. Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 1797-802
47. Granolleras C, Zein A, Oulès R, et al. Continuous administration of intravenous iron during haemodialysis. Nephrol Dial Transplant 1997; 12: 1007-8
48. Sunder-Plassmann G, Hörl WH. Erythropoietin and iron. Clin Nephrol 1997; 47: 141-57
49. Sunder-Plassmann G, Spitzauer S, Hörl WH. The dilemma of evaluating iron status in dialysis patients: limitations of available diagnostic procedures. Nephrol Dial Transplant, 1997; 12: 1575-80
50. Eschbach JW. Turning points: anemia. Dial Transplant 1996; 25: 725-7
51. Eschbach JW, Downing MR, Egrie JC, et al. USA multicenter clinical trial with recombinant human erythropoietin. Contrib Nephrol 1989; 76: 160-5
52. Drücke TB, Barany P, Cazzola M, et al. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clinical Nephrology, 1997; 48: 1-8
53. Hörl WH. How to get the best out of r-HuEPO. Nephrol Dial Transplant 1995; 10 (Suppl. 2): 92-5
54. Cantinieaux BF, Boelaert J, Hariga C, et al. Impaired neutrophil defense against Yersinia enterocolitica In patients with iron overload who are undergoing dialysis. J Lab Clin Med 1988; 111: 524-8
55. Flament J, Goldman M, Waterlot Y, et al. Impairment of phagocyte oxidative metabolism in hemodialyzed patients with iron overload. Clin Nephrol 1986; 25: 227-30
56. Waterlot Y, Cantinieaux B, Hariga-Muller C, et al. Impairment of neutrophil phagocytosis in haemodialysis patients - the critical role of iron overload. BMJ (Clin Res Ed) 1985; 291: 501-4
57. Boclaert JR, Cantinieaux BF, Hariga CF, et al. Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients. Nephrol Dial Transplant 1990; 5: 504-7
58. Van Lenten BJ, Prieve J, Navab M, et al. Lipid-induced changes in intracellular iron homeostasis in vitro and in vivo. J Clin Invest 1995; 95: 2104-10
59. Pang JHS, Jiang MJ, Chen YL, et al. Increased ferritin gene expression in atherosclerotic lesions. J Clin Invest 1996; 97: 2204-12
60. Combe C, Delmas-Beauviex MC, Penchant E, et al. Antioxidant enzymes and erythropoietin therapy in haemodialysed patients supplemented or not with iron [abstract]. Nephrol Dial Transplant 1993; 8: 956-7
61. Patruta SI, Edlinger R, Sunder-Plassmann G, et al. Inhibition of polymorphonuclear leukocyte functions of iron-supplemented, erythropoietin-treated hemodialysis patients. J Am Soc Nephrol. In press
62. Ascherio A, Willett WC, Rimm EB, et al. Dietary iron intake and risk of coronary disease among men. Circulation 1994; 89: 969-74
63. Lauffer RB. Iron stores and the international variation in mortality from coronary artery disease. Med Hypotheses 1991; 35: 96-102
64. Lowrie EG, Huang WH, Lew NL. Death risk predictors among peritoneal dialysis and hemodialysis patients: a preliminary comparison. Am J Kidney Dis 1995; 26: 220-8
65. Magnusson MK, Sigfusson N, Sigvaldason H, et al. Low iron-binding capacity as a risk factor for myocardial infarction. Circulation 1994; 89: 102-8
66. Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men. Circulation 1992; 86: 803-11
67. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981; 1: 1293-4
68. Sullivan JL. Iron and heart disease: dangers of testing the wrong hypothesis [letter). Circulation 1995; 91: 251-2
69. Sempos CT, Looker AC, Gillum RF, et al. Body iron stores and the risk of coronary heart disease. N Engl J Med 1994; 330: 1119-24
70. Ascherio A, Willett WC. Are body iron stores related to the risk of coronary heart disease? N Engl J Med 1994; 16: 1152-3
71. Knekt P, Reunanen A, Tukkunen H, et al. Body, iron stores and risk of cancer. Int J Cancer 1994; 56: 379-82
72. Reizenstein P. Iron, free radicals and cancer. Med Oncol Tumor Pharmacother 1991; 8: 229-33
73. Sussman HH. Iron in cancer. Pathobiology 1992; 60: 2-9
74. Weinberg ED. Iron witholding: a defense against infection and neoplasia. Physiol Rev 1984; 64: 65-102
75. Beare S, Steward WP. Plasma free iron and chemotherapy toxicity. Lancet 1996; 347: 342-3